Research will be focused on fibroblast growth factor-2 (FGF-2).

Neurobiological Technologies and the Buck Institute for Age Research formed a partnership to develop a drug to treat Huntington’s disease (HD). The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that reportedly has neuroprotective properties. Buck scientists will now seek to create a form of FGF-2 that can be moved into clinical trials.


Researchers at the Buck have used FGF-2, in both cell-based and animal models of HD. They report that after being treated with FGF-2, mice with HD showed a 150% increase in new nerve cells, compared to a 30% increase in non-HD mice. Treatment with FGF-2 extended the lifespan of the affected mice by 20%, the Buck team adds. The animals also exhibited improved motor performance, decreased cell death, and a reduction in the amount of toxic aggregates that typically form in the brains of those affected by HD.


“The fact that FGF-2 has such dramatic effects specifically in HD models and is able to cross the blood-brain barrier shows exciting promise as potential new therapy for HD,” remarks Remy Gross, Buck Institute director of business development.

Previous articleEnlisting CROs for Clinical Trial Assistance
Next articlePathway that Causes Death of Premature Newborns Illuminated